CD3-based bispecific antibodies are transforming cancer treatment and showing promise for autoimmune diseases. Nona Biosciences’ HBICE? platform leverages Heavy Chain Only Antibodies (HCAbs) to enhance tumor targeting and immune cell activation. Explore how the HBICE? platform optimizes T Cell Engager (TCE) cytotoxicity while minimizing risks like cytokine release syndrome (CRS). Key Learning Objectives: ? Understand TCEs' role in cancer therapy ? Dive into the MOA of CD3 TCEs ? Discover the potential of CD3 HBICE? for solid tumors with fewer adverse events ?? Learn more: https://lnkd.in/eFBC6Mid #Immunotherapy #CancerTreatment #Biotechnology #TCellEngagers #NonaBiosciences #HBICE #Oncology #AutoimmuneTherapy
Nona Biosciences
生物技术研究
Cambridge，Massachusetts 5,121 位关注者
Empower Global Biotherapeutic Innovation
关于我们
Nona Biosciences is a global biotechnology company committed to providing a total solution for partners worldwide, from academies, biotech startups to biopharma giants. The integrated antibody discovery services range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging the advantages of Harbour Mice? platforms and the experienced therapeutic antibody discovery team. Harbour Mice? generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Integrating Harbour Mice? and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs by diversified partnership strategies including co-discovery, platform and antibody discovery, and platform license. The values of the antibody discovery platforms and flexible partnership models have been well validated by more than 50 industry and academic partners within over 200 projects.
- 网站
-
https://www.nonabio.com/
Nona Biosciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge，Massachusetts
- 类型
- 上市公司
- 创立
- 2022
地点
-
主要
获取路线
1 Broadway
US，Massachusetts，Cambridge，02142
Nona Biosciences员工
动态
-
Will you be attending the Festival of Biologics in Basel from October 15-17? We’re excited to announce that Nona is a Diamond Sponsor this year! Visit us at Booth #736 to learn how our HCAb technology can elevate your biotherapeutic development. Dr. Jiyong Zhang, Nona’s Chief Business Officer, will be presenting on the latest advancements and insights in immunotherapy using our HCAb platform. Be sure to mark your calendar—you won’t want to miss this session! Discover about HCAb Harbour Mice? platform: https://lnkd.in/dfgdKMeH #FestivalofBiologics #FOB #FOB2024 #HCAb #antibodies #biotherapeutics #Biotech #fullyhuman #CART #ADC #multispecific #bispecific #immunotherapy #Tcellengager #TCE
-
-
Explore how the HBICE? platform optimizes TCE cytotoxicity while minimizing adverse events like cytokine release syndrome (CRS) ?? ? Key Learning Objectives: ??Understand the Role of T Cell Engagers (TCEs) in Cancer Therapy ??Explore the Mechanism of Action (MOA) of CD3 TCEs ??Examine the CD3 HBICE? Platform’s Optimization for T Cell Engagement ??Recognize the Therapeutic Potential of CD3 HBICE? in Solid Tumors with Reduced Risk of Adverse Events ? ??Download the white paper here to get more insights: https://lnkd.in/esybdyr3 ? #Immunotherapy #CancerResearch #TCellEngagers #TCE #CD3 #BispecificAntibodies #Biotech #HBICE #Immunotherapy
-
We're pleased to announce that Nona Biosciences has entered a strategic collaboration with Alkyon Therapeutics, a biotechnology company pioneering precision-targeted therapies, to develop next-generation immunotherapeutics and other targeted therapies. This partnership highlights our commitment to applying cutting-edge technology in innovative ways to drive global inventions of transformative next-generation drugs. By leveraging our Harbour Mice? fully human antibody platform and Alkyon's proprietary platform, we will generate deep insights into the tumor microenvironment, advancing novel treatments for solid tumors. Learn more: https://lnkd.in/gFY-yS5A #NonaBiosciences #HarbourMice #immunotherapy #oncology
-
-
Our team had the incredible opportunity to attend the CAR TCR Summit in Boston! We were thrilled to present our HCAb-based CAR discovery platform and engage with top scientists from around the world. Curious about how our platform is generating fully human, highly efficient CAR TCR therapeutic drugs? ?? Visit our website to learn more about this innovative technology and its potential to transform the future of immunotherapy! https://lnkd.in/ePDGfAwn #CARTCR #Immunotherapy #Innovation #CARTcell #CART #HCAb #antibodies #Therapeutics #Biotech
-
-
Nona Biosciences is attending the CAR-TCR Summit in Boston, MA, from September 17-20. Visit us at Booth #64 to explore our latest innovations in CAR-T technology and learn more about our HCAb platform! Our dedicated scientific team will be on-site to answer all your questions and provide insights into how our fully human heavy chain only antibodies are shaping the future of biotherapeutics. Hope to see you there! Learn more about our HCAb based CAR discovery platform: https://lnkd.in/ePDGfAwn #CARTCR #CARTCRsummit #CARTCR2024 #CART #Immunotherapy #CellTherapy #NextGenBiotherapeutics #Innovation #Biotech #BostonSummit #Oncology
-
-
?? Register Now: https://lnkd.in/d6x8uq2s Highlights: ??The power of the HCAb Harbour Mice? platform in developing innovative immune-therapeutics. ??Advancements in HBICE? for bispecific and multispecific antibody technologies. ??Cutting-edge applications in HCAb-ADCs, CAR-T, and mRNA therapies. Don’t miss this chance to explore the future of immunotherapy! #webinar #biotech #therapeutics #innovation #immunotherapy #drugdiscovery #NonaBiosciences
Join us for an exciting deep dive into the world of advanced therapeutics! Our upcoming webinar "?????????????????? ????????????????????????: ???????????????????? ???????? ?????????????? ????????? ?????? ??????????-???????????????? ????????????????????, ??????-??, ????????, ?????? ???????? ??????????????????????" will showcase how the HCAb Harbour Mice? platform is revolutionizing the development of next-generation therapies. ?? Register Today: https://lnkd.in/eYgsuj44 Speaker: Dr. Joe Zhao, Head of External Innovation, Nona Biosciences Key Highlights: ?? Explore the HCAb Harbour Mice? platform, designed to produce heavy chain-only antibodies advancing in immune-therapeutics. ?? The development of HBICE (HCAb -Based Immune Cell Engager) and how to utilize the HBICE? platform to develop bispecific and multispecific antibody technologies, particularly in enhancing T cell engagement (TCE), to advance immunotherapy. ?? Cutting-edge innovations in the application prospects of Nona HCAb-ADCs CAR-T and mRNA therapies in their crucial role in driving new therapeutic approaches. Don’t miss out on this opportunity to expand your knowledge and discuss the future of immune-therapeutics. #webinar #biotechnology #therapeutics #innovation #immunotherapy #drugdiscovery #NonaBiosciences
此处无法显示此内容
在领英 APP 中访问此内容等
-
?? Exciting news from Nona Biosciences! We are thrilled to announce our new antibody discovery collaboration with Umoja Biopharma, a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies in oncology and autoimmunity. This partnership will leverage Nona’s cutting-edge fully human heavy chain only antibody (HCAb) technology to produce innovative in vivo generated CAR-T cell therapy drug candidates. By combining our HCAb Harbour Mice? platform and NonaCarFx? screening technology with Umoja's advanced VivoVec? platform, we are confident to develop novel in vivo CAR-T cell therapies and expand the potential reach of this innovative delivery technology. Stay tuned as we work together to push the boundaries of what's possible in CAR-T therapy! Learn more: https://lnkd.in/gjure2CP #NonaBiosciences #HCAb #CART #Innovation
-
-
?? T Cell Engagers: The Next Leap in Pharma's Evolution! ?? ?? From revolutionary CAR-T therapies to the revival of TCEs, the path traversed by T cell-targeting therapies keeps changing oncology and beyond. ?? After the landmark approvals from the year 2024, the treatments for these autoimmune diseases are most likely to change with TCEs into safer and more versatile options. ?? Nona Biosciences is paving the way for this innovation, breaking barriers with advanced CD3 binders and HBICE?. (Check here: https://lnkd.in/ev58UnVH) ?? Curious about how the future of TCEs will look? You can find more in the complete roadmap right here! View the full blog post here: https://lnkd.in/ekncKKxk #biotechnology #innovation #TCETherapies #Immunology #CART #AutoimmuneDisease
-
?? Exciting News! Nona Biosciences is partaking in the CAR-TCR Summit in Boston, MA, from September 17-20. Be sure to visit us at Booth #64 to discover our latest breakthroughs in CAR-T innovations! Don't miss Dr. Musheng Bao’s presentation, "Nona's Fully Human Heavy Chain Only Antibodies to Develop Next-Gen Biotherapeutics," happening on Day 2 at 2:35 PM. Plus, make sure to catch our Poster Presentation (#22): "Fully Human Heavy Chain Only Antibodies to BCMA Identified by NonaCarFx? Platform." We look forward to sharing our advancements and discussing how we can collaborate to push the boundaries of cell therapy! Learn more about our cutting-edge CAR-T capabilities at Nona Biosciences. https://lnkd.in/ePDGfAwn #CART #Immunotherapy #CellTherapy #NextGenBiotherapeutics #NonaBiosciences #Innovation #Biotech #BostonSummit #Oncology
-